Results from the largest-ever clinical trial of its kind found administering a synthetic protein can reduce bleeding and improve outcomes for certain patients at the highest risk of continued bleeding following a type of stroke called an intracerebral hemorrhage (ICH).
This article was originally published on MedicalXpress.com

